Outcomes of limited period of adalimumab treatment in moderate to severe Crohn's disease patients: Taiwan Society of Inflammatory Bowel Disease Study

BACKGROUND/AIMS: In Taiwan, due to budget limitations, the National Health Insurance only allows for a limited period of biologics use in treating moderate to severe Crohn's disease (CD). We aimed to access the outcomes of CD patients following a limited period use of biologics, specifically fo...

Descripción completa

Detalles Bibliográficos
Autores principales: Lin, Wei-Chen, Chou, Jen-Wei, Yen, Hsu-Heng, Hsu, Wen-Hung, Lin, Hung-Hsin, Lin, Jen-Kou, Chuang, Chiao-Hsiung, Huang, Tien-Yu, Wang, Horng-Yuan, Wei, Shu-Chen, Wong, Jau-Min
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Korean Association for the Study of Intestinal Diseases 2017
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5683979/
https://www.ncbi.nlm.nih.gov/pubmed/29142516
http://dx.doi.org/10.5217/ir.2017.15.4.487

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5683979/
https://www.ncbi.nlm.nih.gov/pubmed/29142516
http://dx.doi.org/10.5217/ir.2017.15.4.487

Ejemplares similares